People
-
OINDP specialist CDMO Kenox Pharmaceuticals has announced the appointment of Julianne Berry as VP of R&D and Manufacturing. Berry was most recently VP, Respiratory Product Development at Odin Pharmaceuticals and has extensive experience in the development of inhaled… Read more . . .
-
Inhalation CDMO Bespak has announced the appointment of former automotive industry executive Tarik Hage as Chief Commercial Officer. Hage was most recently VP of Commercial and Business Development at GKN Automotive, where he had worked… Read more . . .
-
Inhaled drug developer Avalyn Pharma has announced the appointments of Jill Denning as Senior VP, Clinical Development Operations, and Kimberley Cummings as Senior VP, Regulatory Affairs. Denning was most recently VP of Clinical Development at Kinevant… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced the appointment of Ajay Ahuja as Executive VP and Chief Medical Officer. Ahuja was most recently Development and Launch Leader at Kardigan Bio; his previous experience includes executive roles at… Read more . . .
-
Inhaler testing specialist Copley Scientific has announced the appointment of Paul Martin as Head of Business Development. Martin, who has extensive experience in business development within the OINDP space, was most recently Associate Director of… Read more . . .
-
According to Corstasis Therapeutics, the FDA has approved the company’s NDA for Enbumyst (RSQ-777) bumetanide nasal spray for the treatment of edema associated with heart, kidney, and liver disease. In January 2025, Corstasis announced that… Read more . . .
-
Inhaled epinephrine developer De Motu Cordis (DMC) announced that its CEO Peter O’Neill has stepped down and that Chief Financial Officer John Corbett will serve as Interim CEO. The company says that it is preparing… Read more . . .
-
Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .
-
Startup Mosanna Therapeutics announced that it has closed a $80 million Series A financing that will fund Phase 2 development of the company’s MOS118 nasal spray for the treatment of obstructive sleep apnea. Mosanna also announced the… Read more . . .
-
Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK



